A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 24 Apr 2012 Additional lead trial investigator (Dr. Senu Apewokin) identified as reported by ClinicalTrials.gov.
- 19 Apr 2012 Planned end date changed from 1 Feb 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 29 Sep 2011 Planned end date changed from 1 Nov 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.